Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for
- PDF / 409,429 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 16 Downloads / 238 Views
ORIGINAL ARTICLE
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity? Maximilian Tscharre 1,2 & Patricia P. Wadowski 2 & Constantin Weikert 2 & Joseph Pultar 2 & Beate Eichelberger 3 & Simon Panzer 3 & Thomas Gremmel 2,4 Accepted: 10 December 2020 # The Author(s) 2020
Abstract Background In patients with acute coronary syndrome (ACS), angiotensin-converting enzyme (ACE) inhibitors are preferred over angiotensin receptor blockers (ARBs). However, in a recent pilot study, treatment with ACE inhibitors was associated with increased platelet reactivity compared to ARBs. Therefore, we sought to investigate the impact of renin-angiotensin-aldosterone system (RAAS) blockade with ACE inhibitors and ARBs on platelet aggregation in patients with ACS undergoing percutaneous coronary intervention. Methods On-treatment residual platelet reactivity in response to arachidonic acid (AA), adenosine diphosphate (ADP), SFLLRN, AYPGKF, and collagen was assessed by multiple electrode aggregometry (MEA) in 197 ACS patients on dual antiplatelet therapy (DAPT) with aspirin and either prasugrel or ticagrelor. Results One hundred sixty-five (83.7%) patients were treated with ACE inhibitors, 32 (16.3%) with ARBs. On-treatment residual AA- and ADP-inducible platelet reactivity was significantly higher in patients with ACE inhibitors (both p < 0.05). Likewise, SFLLRN was significantly higher in patients with ACE inhibitors (p = 0.036) and there was a trend for higher AYPGKF- and collagen-inducible platelet reactivity (p = 0.053 and p = 0.082). The incidence of high on-treatment residual platelet reactivity AA was significantly higher in patients with ACE inhibitors (52 [31.5%] vs. 3 [9.4%] patients; p = 0.019). Conclusion ACE inhibitors are associated with increased on-treatment residual platelet reactivity in ACS patients with potent DAPT. Further clinical trials are needed to elucidate the role of RAAS blockade with ACE inhibitors and ARBs in ACS patients treated according to current standards. Keywords Angiotensin-converting enzyme inhibitors . Angiotensin receptor blockers . Acute coronary syndromes . Multiple electrode aggregometry . Platelet reactivity
Introduction
* Thomas Gremmel [email protected] 1
Department of Internal Medicine, Cardiology and Nephrology, Landesklinikum Wiener Neustadt, Wiener Neustadt, Austria
2
Department of Internal Medicine II, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria
3
Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria
4
Department of Internal Medicine I, Cardiology and Intensive Care Medicine, Landesklinikum Mistelbach-Gänserndorf, Mistelbach, Austria
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is the antithrombotic standard regimen for patients presenting with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) [1–3]. Prasugrel and ticagrelor are newer
Data Loading...
